Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design.
Castaño-Vinyals G, Aragonés N, Pérez-Gómez B, Martín V, Llorca J, Moreno V, Altzibar JM, Ardanaz E, de Sanjosé S, Jiménez-Moleón JJ, Tardón A, Alguacil J, Peiró R, Marcos-Gragera R, Navarro C, Pollán M, Kogevinas M; MCC-Spain Study Group. Castaño-Vinyals G, et al. Gac Sanit. 2015 Jul-Aug;29(4):308-15. doi: 10.1016/j.gaceta.2014.12.003. Epub 2015 Jan 19. Gac Sanit. 2015. PMID: 25613680 Free article.
Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems.
Perea G, Altés A, Montoto S, López-Guillermo A, Domingo-Doménech E, Fernández-Sevilla A, Ribera JM, Grau J, Pedro C, Angel Hernández J, Estany C, Briones J, Martino R, Sureda A, Sierra J, Montserrat E. Perea G, et al. Ann Oncol. 2005 Sep;16(9):1508-13. doi: 10.1093/annonc/mdi269. Epub 2005 Jun 6. Ann Oncol. 2005. PMID: 15939718 Free article.
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO). Martínez C, et al. Br J Haematol. 2016 Sep;174(6):859-67. doi: 10.1111/bjh.14133. Epub 2016 May 17. Br J Haematol. 2016. PMID: 27185197 Free article. Clinical Trial.
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea). González-Barca E, et al. Acta Haematol. 2016;136(2):76-84. doi: 10.1159/000444625. Epub 2016 May 18. Acta Haematol. 2016. PMID: 27188649 Clinical Trial.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C. Garcia-Sanz R, et al. Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009. Ann Oncol. 2019. PMID: 30657848 Free article. Clinical Trial.
m7FLIPI and targeted sequencing in high-risk follicular lymphoma.
Sorigue M, Oliveira A, Mercadal S, Tapia G, Climent F, Perez-Roca L, Lorences I, Domingo-Domenech E, Cabezon M, Navarro JT, Gonzalez-Barca E, Zamora L, Ribera JM, Sureda A, Armengol MP, Sancho JM. Sorigue M, et al. Hematol Oncol. 2019 Dec;37(5):564-568. doi: 10.1002/hon.2674. Epub 2019 Oct 25. Hematol Oncol. 2019. PMID: 31475375
Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Salas MQ, Mercadal S, Domingo Domenech E, Oliveira AC, Encuentra M, Climent F, Andrade Campos M, Aguilera C, Fernández de Sevilla A, Sureda A, González-Barca E. Salas MQ, et al. Leuk Lymphoma. 2020 Mar;61(3):575-581. doi: 10.1080/10428194.2019.1683733. Epub 2019 Nov 5. Leuk Lymphoma. 2020. PMID: 31684781
98 results